Desloratadine-d4 (hydrobromide)

• UNSPSC Description:

  Desloratadine-d4 hydrobromide is deuterated labeled Desloratadine (HY-B0539). Desloratadine (Sch34117) is the orally active major metabolite of the nonsedating H1-antihistamine Loratadine. Desloratadine is a selective H1-receptor antagonist that has anti-allergic and anti-inflammatory activities[1][2].

• Target Antigen:

  Drug Metabolite; Endogenous Metabolite; Histamine Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation;Metabolic Enzyme/Protease;Neuronal Signaling;Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Endocrinology; Inflammation/Immunology

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C(NC([2H])C/1[2H])C([2H])C1=C2C3=CC=C(Cl)C=C3CCC4=CC=CN=C4\2.Br

• Molecular Weight:

  395.76

• References & Citations:

  [1]McClellan K, et al. Desloratadine. Drugs. 2001;61(6):789-797.|[2]Geha, R.S. and E.O. Meltzer, Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol, 2001. 107(4): p. 751-62.|[3]Schroeder, J.T., et al., Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy, 2001. 31(9): p. 1369-77.|[4]Anthes, J.C., et al., Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol, 2002. 449(3): p. 229-37.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported